The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells

Previous studies have suggested that histone methylation can modulate carcinogenesis and cancer progression. For instance, the histone methyltransferase SET and MYND domain containing 2 (SMYD2) is overexpressed in several types of cancer tissue. The aim of the present study was to determine whether...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Oncol Lett
Main Authors: Kojima, Machiko, Sone, Kenbun, Oda, Katsutoshi, Hamamoto, Ryuji, Kaneko, Syuzo, Oki, Shinya, Kukita, Asako, Kawata, Akira, Honjoh, Harunori, Kawata, Yoshiko, Kashiyama, Tomoko, Sato, Masakazu, Taguchi, Ayumi, Miyamoto, Yuichiro, Tanikawa, Michihiro, Tsuruga, Tetsushi, Nagasaka, Kazunori, Wada-Hiraike, Osamu, Osuga, Yutaka, Fujii, Tomoyuki
פורמט: Artigo
שפה:Inglês
יצא לאור: D.A. Spandidos 2020
נושאים:
Articles
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7471656/
https://ncbi.nlm.nih.gov/pubmed/32934721
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2020.12014
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים